Vox Biomedical Receives NIH Award for Rapid COVID-19 Diagnostic Development

September 28, 2020

Vox Biomedical announced that it has received a supplemental award from the National Institute on Drug Abuse, part of the National Institutes of Health, to expand upon the breath analyzer technology, which it is developing for the detection of marijuana and opioids, to include a rapid, sensitive and accurate breath diagnostic test for COVID-19.

Vox Biomedical reports the award calls for a biomarker discovery effort to determine the exhaled breath molecular species most suitable for use as a COVID-19 biomarker and methods of capture that can be implemented within the safety paradigm governing COVID-19 testing.

Exhaled breath is a rich matrix of volatile organic compounds or VOCs, originating from human metabolism as well as aerosol condensates and bacterial and viral species suspended in micro-water droplets and inflammatory products. Towards the end of developing a breath-based COVID-19 diagnostic, Vox Biomedical scientists will investigate biomolecules associated with the inflammatory and metabolic changes caused by COVID-19 infection. In addition, Vox Biomedical scientists will consult with Dr. Scott Lukas of McLean Hospital and Harvard Medical School to determine substance abuse molecules that can be simultaneously captured along with a COVID-19 biomarker in the exhaled breath. This effort will allow future studies to determine the effect of COVID-19 infection on substance abuse communities.

Upon identification of potential COVID-19 breath-based biomarkers detection, efforts will concentrate on breath collection and virus detection utilizing Vox’s current portable instrument design. An FDA regulatory approval strategy for such a COVID-19 diagnostic technique will be developed to aid in the rapid deployment of this diagnostic technique once validation of a COVID-19 biomarker has been established.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy